Antisecretory Factor for Newly Diagnosed Glioblastoma
Antisecretory Factor Glioblastoma Phase 2
Recruiting
Phase 2
Phase 3
Interventional Study
Glioblastoma
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 300 (estimated)
- Sponsor
- Peter Siesjö · Other
Who this trial is looking for
This trial is looking for adults with newly diagnosed glioblastoma. Participants will take either an egg powder containing a special factor or a placebo daily around the time they receive chemotherapy and radiotherapy.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with glioblastoma or grade 4 astrocytoma.
- I am between 18 and 75 years old.
- I have had surgical treatment for my tumor.
- I am scheduled to receive radiochemotherapy or chemotherapy.
- I can provide informed consent.
You may not be able to join if
- I cannot provide informed consent.
- I am allergic to egg yolk.
- I have only had a surgical biopsy.
- I will only receive radiotherapy.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are ove…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Pathology verified glioblastoma or astrocytoma grade 4
2. Age 18-75 years
3. Surgical treatment-resection.
4. Scheduled concomitant radiochemotherapy, or only chemotherapy.
5. Informed consent
Exclusion Criteria:
1. No informed consent
2. Egg yolk allergy
3. Only surgical b…
Contacts
Johan Bengzon, MD, PhD
CONTACT